Patient leaflet - Certifect
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Active substances:
Each unit dose delivers:
| CERTIFECT spot-on solution | Volume of unit dose (ml) | Fipronil (mg) | (S)-Methoprene (mg) | Amitraz (mg) |
| dogs 2–10 kg | 1.07 | 67 / | 60.3 | 80 |
| dogs 10–20 kg | 2.14 | 134 | 120.6 | 160 |
| dogs 20–40 kg | 4.28 | 241.2 | 320 | |
| dogs 40–60 kg | 6.42 | 402 ) | 361.8 | 480 |
Excipients:
Butylhydroxyanisole (0.02 %)
Butylhydroxytoluene (0.01 %)
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Spot-on solution.
Clear amber to yellowish solution.
-
4. CLINICAL PARTICULARS
4.1 Target species
Dogs
4.2 Indications for use, specifying the target species
Treatment and pr vention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulatus, Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and fleas (Ctenocephalides felis and Ctenocephalides canis).
Treatment of infestations by chewing lice (Trichodectes canis ).
Prevention of environmental flea contamination by inhibiting the development of all flea immature stages. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD). Elimination of fleas and ticks within 24 hours. One treatment prevents further infestations for 5 weeks by ticks and for up to 5 weeks by fleas.
The treatment indirectly reduces the risk of transmission of tick-borne diseases (canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis) from infected ticks for 4 weeks.
4.3 Contraindications
Do not use on sick (e.g. systemic diseases, diabetes, fever) or convalescent animals. Do not use in rabbits and cats.
4.4 Special warnings for each target species
The veterinary medicinal product remains effective after exposure to sunlight or i becomes wet after rain, bathing, or water immersion. However, shampooing or i animal in water directly after treatment or frequent shampooing may reduce the these cases do not treat more frequently than once a fortnight. Treated animals s until 48 hours after treatment. If the dog requires shampooing, it is better to do s veterinary medicinal product.
animal rsion of the tion of activity. In ould not be bathed before applying the
All stages of fleas can infest the dog's basket, bedding and regular rest eas such as carpets and soft furnishings. In case of massive flea infestation and at the beginning of the control measures these areas should be treated with a suitable environmental product an acuumed regularly.
After treatment with CERTIFECT ticks will generally be kill off the dog within 24 hours
after infestation without having a blood meal. However the a ment of single ticks after treatment cannot be excluded. For this reason the transmission of infectious diseases cannot be completely excluded if conditions are unfavourable.
4.5 Special precautions for use
Special precautions for use in animals
Avoid contact with the dog's eyes.
Spot-on application only. Do not administer orally or via any other route. The treated area may appear wet or oily after treatment.
In the absence of additional safety 2 weeks, do not treat puppies less
s, do not repeat the treatment at intervals of less than weeks of age, and dogs less than 2 kg bodyweight (b.w.).
This veterinary medicinal product contains amitraz, which is a monoamine oxidase inhibitor (MAOI); therefore, in the absence of s, this veterinary medicinal product should not be used on dogs treated with MAOI.
Dogs should be prevented from accessing streams and rivers for 48-hours following treatment (see section 6.6).
Special precaution animals
aken by the person administering the veterinary medicinal product to
This veterina icinal product may cause skin sensitisation, allergic reactions and mild eye irritation in. Animals or persons with a known hypersensitivity to any of the active ingredien ipients should avoid contact which, on very rare occasions, can cause respiratory irritation ermal reactions in certain individuals. The use of protective gloves is recommended. Avoid direct contact with the application site. Children should not be allowed to play with treated
do
the application site is dry. It is therefore recommended that dogs are not treated during the uring the early evening, and that recently treated animals are not allowed to sleep with
, especially children.
This veterinary medicinal product contains amitraz, which can lead to neurological side-effects in humans. Amitraz is a monoamine oxidase inhibitor (MAOI); therefore, people taking MAOI-containing medication should take particular care and avoid direct contact with the product. To minimise the potential for inhalation, apply in the open air or in a well ventilated area.
Do not smoke, drink or eat whilst handling.
Wash hands thoroughly after use.
Used pipettes should be disposed of immediately. Stored pipettes must be kept in the intact foil package.
In case of accidental spillage onto skin, wash off immediately with soap and water. If it accidentally gets into the eyes, they should be thoroughly flushed with water.
In case of incorrect use, seek medical advice immediately and show the package leaflet or the label to the physician.
If side effects are noted, seek immediate medical assistance and show the package leaflet or label to the physician.
4.6 Adverse reactions (frequency and seriousness)
Transient skin reactions at the application site (skin discolouration, local hair loss, itching, redness) and general itching or hair loss may occur on rare occasions. Lethargy, ataxia, emesis, anorexia, diarrhoea, excessive salivation, hyperglycaemia, increased sensitivity to stimulation, bradycardia or bradypnea may be observed. Signs are transitory and generally resolve without treatment within 24 hours.
In very rare instances, certain sensitive dogs may develop skin irritation at the application site. Other forms of dermatitis including pemphigus-like conditions may occur in even rarer instances. Should this occur, contact your veterinarian promptly for treatment advice and discontinue use of the product.
The frequency of adverse reactions is defined using the following convention:
-
– very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment)
-
– common (more than 1 but less than 10 animals in 100 animals)
-
– uncommon (more than 1 but less than 10 animals in 1,000 animals)
-
– rare (more than 1 but less than 10 animals in 10,000 animals)
-
– very rare (less than 1 animal in 10,000 animals, including isolated reports).
4.7 Use during pregnancy, lactation or lay
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses of up to 3 times the maximum recommended dose.
Can be used during pregnancy and lactation.
4.8 Interaction with other medicinal products and other forms of interaction
No data available.
4.9 Amounts to be administered and administration route
Dose:
The recommended minimum dose is 6.7 mg/kg bodyweight for fipronil, 6 mg/kg for (S)-methoprene
and 8 mg/kg for amitraz.
Each unit dose (dual cavity pipette) delivers:
| CERTIFECT spot-on solution | Volume of unit dose (ml) | Fipronil (mg) | S-methoprene (mg) | 0 |
| dogs 2–10 kg | 1.07 | 67 | 60.3 > | 80 |
| dogs 10–20 kg | 2.14 | 134 | 120.6 | 160 |
| dogs 20–40 kg | 4.28 | 268 | 241.2 | > 320 |
| dogs 40–60 kg | 6.42 | 402 | 361.8 | 480 |
Treatment schedule:
Monthly intervals throughout the tick and/or flea seasons, based on local epidemiological situations.
Advice on correct administration:
Select the appropriate pipette size for the weight of the dog. For dogs over 60 kg, use the appropriate combination of two pipettes that most closely matches the bodyweight.
Method of administration:
Spot-on use.
For a pack of 3, first separate one blister from the others by tearing along the perforation.
Use a pair of scissors to cut the blister along the dotted line (or fold on the corner as shown and pull the foil away).
Remove the pipette and hold it upright.
Cut off the pipette tip with a pair of scissors. Part the coat until the skin is visible. Place the tip of the pipette on the skin. Squeeze the pipette, apply about half of the contents half way down the neck between the base of the skull and the shoulder blades. Repeat the application at the base of the neck in front of the shoulder blades to empty the pipette.
4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
Safety has been demonstrated with up to 5 times the recommended dose in healthy adult dogs (treated up to 6 times at two-week intervals) and in puppies (aged 8 weeks treated once).
Safety was also demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses of up to 3 times the maximum recommended dose.
The risk of experiencing adverse reactions (see section 4.6) may however increase with overdosing, so animals should always be treated with the correct pipette size according to bodyweight.
Known side-effects of amitraz and its metabolites are due to alpha-2-adreno-receptor agonist effects. They may consist of hypersalivation, vomiting, lethargy, hyperglycaemia, bradycardia or bradypnea. Signs are transitory and generally resolve without treatment within 24 hours.
If symptoms are severe or persist, alternatively the antidote alpha-2-adreno-receptor antagonist atipamezole hydrochloride may be used.
4.11 Withdrawal period(s)
Not applicable.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: Other ectoparasiticides for topical use.
ATCvet code: QP53AX65.
The veterinary medicinal product is an insecticidal and acaricidal solution for topical use, containi adulticidal active ingredients, fipronil and amitraz, in combination with an ovicidal and larvicidal active ingredient, (S)-methoprene.
5.1 Pharmacodynamic properties
r acari.
Fipronil is an insecticide and acaricide belonging to the phenylpyrazole family. Fipron metabolite fipronil sulfone act at ligand-gated chloride channels, in particular those ga neurotransmitter gamma-aminobutyric acid (GABA) as well as desensitising (D) and desensitising (N) channels gated by glutamate (Glu, unique invertebrate ligand-gate channels), thereby blocking pre- and post-synaptic transfer of chloride ions acr
l membranes.
This results in uncontrolled activity of the central nervous system and death of i
(S)-Methoprene is an insect growth regulator (IGR) of the class of compounds known as juvenile hormone analogues that inhibit the development of immature stages of insects. This compound mimics the action of juvenile hormone and causes impaired development and death of the developing
stages of fleas. The on-animal ovicidal activity of (S)-methoprene res penetration of the eggshell of newly laid eggs or from absorption thr (S)-methoprene is also effective in preventing flea larvae and pupa contamination of the environment of the treated animals with th
Amitraz is a formamidine acaricide that acts as an agonist on stimulation of octopaminergic synapses in acari, resulting in sublethal concentrations these compounds have the ability to
s from either direct
e cuticle of the adult fleas. developing, which prevents re stages of fleas.
their reproduction. Specific tick detachment propertie
e receptors causing an over-mors and convulsions. Moreover, at use anorexia in acari and suppress
ibed as an expellant action causing ticks
to withdraw their mouthparts rapidly and fall off the host animal have been reported for amitraz.
The combination of amitraz and fipronil acts on m sites of the nervous systems of ticks. A low dose of amitraz together with fipronil has shown synergistic efficacy against ticks resulting in an increased speed of kill (starting at 2 hours and greater than 90 % at 24 hours) and a longer duration of activity when compared to the active substances administered alone.
CERTIFECT treatment causes detachment of ticks when applied to a dog with a pre-existing infestation, disrupts attachment and rapidly kills ticks within 24 hours thus inhibiting the blood meal and the concomitant risk of transmission of tick-borne pathogens. The risk of developing canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis for 4 weeks is thereby indirectly reduced.
lars
Studies have demonstrated t mammals between fiproni
5.2 Pharmacokinetic pa
Systemic absorptio administration
Fipronil: Ab: plasma foun by approxim
is no pharmacodynamic and pharmacokinetic interaction in thoprene and amitraz.
TIFECT is low for all three active substances following topical
vailability: 9.5 %. The mean maximum concentration (Cmax): 19 ng/ml in
ys (Tmax). Plasma concentrations were below 1 ng/ml (limit of quantification) 3 days following topical administration.
(S)-Methoprene and Amitraz : Dermal absorption is very low and all plasma concentrations were below the limit of quantification (10 ng/ml) for (S)-methoprene and were undetectable for amitraz (< 0.75 ng/ml) in most samples.
Distribution, metabolism, and excretion
Fipronil’s major metabolite on the haircoat of the dog and in the blood stream is the sulfone derivative. Fipronil sulfone is produced on the haircoat (mean concentrations < 16 % of fipronil during the first month after treatment).
(S)-Methoprene is extensively degraded into carbon dioxide and acetate that are subsequently incorporated into endogenous materials.
Amitraz degrades on the haircoat of the dog into N-methyl-N’-(2,4-xylyl) formamidine (< 5 % of amitraz concentrations). Small concentrations of dimethylaniline, a minor degradation product of amitraz, were also observed on the haircoat of the dog post-application but in negligible quantities.
A pharmacokinetic study in dogs, of the active substances alone and in combination, showed that no drug interactions occur between the active substances that affect their pharmacokinetic parameters.
The three active substances are well distributed over the haircoat of the dog during the first week after application. The concentrations of fipronil, fipronil sulfone, amitraz and S-methoprene in the haircoat then decrease with time and are detectable for at least 58 days after dosing. Major metabolites are distributed over the entire haircoat of the dog. Fipronil sulfone decreased to concentrations of < 0.6 ^g/g by 58 days after topical application. Low levels of N-metl were detectable for 30 days after dosing.
2,4-xylyl) formamidine
Environmental properties
CERTIFECT should not enter water courses as this may be dangerous for fish and aquatic organisms.
-
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Butylhydroxyanisole (E320)
Butylhydroxytoluene (E321)
6.2 Incompatibilities
None known
6.3 Shelf life
For the 1.07 ml pipette:
Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
For the 2.14 ml, 4.28 ml or 6.42 ml pipette:
Shelf life of the veterinary medicinal product as packaged for sale: 3 years.
6.4 Special precautions for storage
Sto
6.5 Nature and composition of immediate packaging
Purple dual chamber pipette: The primary packaging is composed of two heat-formed polyolefin chambers with a central polyolefin-coated aluminium partition. The secondary packaging consists of plastic/ aluminium blister with a plastic/ aluminium backing.
| CERTIFECT spot-on solution | Volume of unit dose (ml) | card | carton box Z" |
| dogs 2–10 kg | 1.07 | 1 pipette | 3 pipettes |
| dogs 10–20 kg | 2.14 | 1 pipette | 3 pipettes |
| dogs 20–40 kg | 4.28 | 1 pipette | 3 pipettes |
| dogs 40–60 kg | 6.42 | 1 pipette | 3 pipettes |
Not all pack sizes may be marketed.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
Any unused veterinary medicinal product or waste material derived from it should be disposed of in accordance with local requirements and should not enter water courses as this may be dangerous for fish and aquatic organisms.
7. MARKETING AUTHORISATION HOLDER
MERIAL
29, avenue Tony Garnier
FR-69007 Lyon
France
8. MARKETING AUTHORISATION NUMBER(S)
EU/2/11/125/001–008
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
Date of first authorisation: 06/05/2011.
Date of latest renewal:
10. DATE OF REVISION OF THE TEXT
Detailed information on this veterinary medicinal product is available on the website of the European
Medicines Agency
PROHIBITION OF SALE, SUPPLY AND/OR USE
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Each 1.07 ml of solution contains: Fipronil 67 mg, (S)-Methoprene 60.3 mg, Amitraz 80 mg
Each 2.14 ml of solution contains: Fipronil 134 mg, (S)-Methoprene 120.6 mg, Amitraz 160 mg
Each 4.28 ml of solution contains: Fipronil 268 mg, (S)-Methoprene 241.2 mg, Amitraz 320 mg
Each 6.42 ml of solution contains: Fipronil 402 mg, (S)-Methoprene 361.8 mg, Amitraz 480 mg
3. PHARMACEUTICAL FORM
Spot-on solution
4. PACKAGE SIZE
-
3 × 1.07 ml
3 × 2.14 ml
3 × 4.28 ml
3 × 6.42 ml
5. TARGET SPECIES
Dogs 2–10 kg
Dogs 10–20 kg
Dogs 20–40 kg
Dogs 40–60 kg
6. INDICATI
7. ME
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES
Each 1.07 ml of solution contains: Fipronil 67 mg, (S)-Methoprene 60.3 mg, Amitraz 80 mg
Each 2.14 ml of solution contains: Fipronil 134 mg, (S)-Methoprene 120.6 mg, Amitraz 160 mg
Each 4.28 ml of solution contains: Fipronil 268 mg, (S)-Methoprene 241.2 mg, Amitraz 320 mg
Each 6.42 ml of solution contains: Fipronil 402 mg, (S)-Methoprene 361.8 mg, Amitraz 480 mg
4. PACKAGE SIZE
1 × 2.14 ml
1 × 4.28 ml
1 × 6.42 ml
5. TARGET SPECIES
Dogs 2–10 kg
Dogs 10–20 kg
Dogs 20–40 kg
Dogs 40–60 kg
6. INDICATI
7. ME
Spot-on use.
Read the package leaflet before use.
11. SPECIAL STORAGE CONDITIONS
Store in the original package.
-
12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR
WASTE MATERIALS, IF ANY
Read the package leaflet before use.
-
13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR
RESTRICTIONS REGARDING SUPPLY AND USE, if applicable
For animal treatment only.
To be supplied only on veterinary prescriptio
-
14. THE WORDS “KEEP OUT O F THE SIGHTAND REACH OF CHILDREN”
Keep out of the sight and reach of children.
-
15. NAME AND ADD R ESS OF THE MARKETING AUTHORISATION HOLDER
MERIAL
29, avenue Tony Garnier
FR-69007 Lyon
France.
-
16. MARKETING AUTHORISATION NUMBER(S)
EU/2/11/125/001
EU/2/11/125/002
EU/2/11/125/003
EU/2/11/125/004
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
FOIL – For all pack sizes
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT
1.07 ml
2.14 ml
4.28 ml
6.42 ml
2. NAME OF THE MARKETING AUTHORISATION HOLDER
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
PIPETTE LABEL
CERTIFECT
4. ROUTE(S) OF ADMINISTRATION
1. NAME OF THE VETERINARY MEDICINAL PRODUCT
2. QUANTITY OF THE ACTIVE SUBSTANCE(S)
3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER O
1.07 ml
2.14 ml
4.28 ml
6.42 ml
E OF THE MARKETING AUTHORISATION HOLDER
5. WITHDRAWAL PERI
6. BATCH NUMBE
SES
{number}
{month
8.
7. EXPI
L
PACKAGE LEAFLET FOR (Box of 3 pipettes)
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder:
MERIAL
29, avenue Tony Garnier
FR-69007 Lyon
France.
Manufacturer responsible for the batch release:
MERIAL
4, Chemin du Calquet
FR-31000 Toulouse Cedex
France
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS
Spot-on solution.
Clear amber to yellowish solution.
Each unit dose (dual cavity pipette) delivers:
| CERTIFECT spot-on solution _____ zx? | Volume of unit dose (ml) | Fipronil (mg) | (S)-methoprene (mg) | Amitraz (mg) |
| dogs 2–10 kg | 1.07 | 67.0 | 60.3 | 80.0 |
| dogs 10–20 kg | 2.14 | 134.0 | 120.6 | 160.0 |
| dogs 20–40 kg | 4.28 | 268.0 | 241.2 | 320.0 |
| w fl dogs 40–60 kg | 6.42 | 402.0 | 361.8 | 480.0 |
Excipients essential for proper administration: butylhydroxyanisole (0.02 %) and butylhydroxytoluene (0.01 %).
4. INDICATIONS
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulat Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and flea (Ctenocephalides felis and Ctenocephalides canis).
Treatment of infestations by chewing lice (Trichodectes canis ).
mature
ermatitis
Prevention of environmental flea contamination by inhibiting the development of a stages.
The product can be used as part of a treatment strategy for the control of Flea A (FAD).
Elimination of fleas and ticks within 24 hours. One treatment prevents by ticks and for up to 5 weeks by fleas.
The treatment indirectly reduces the risk of transmission of tick-borne monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis) fro
5. CONTRAINDICATIONS
stations for 5 weeks
babesiosis, for 4 weeks.
Do not use on sick (e.g. systemic diseases, diabetes, fever) or convalescent animals.
Do not use in rabbits and cats. rv
6. ADVERSE REACTIONS
Transient skin reactions at the application site (skin discolouration, local hair loss, itching, redness) and general itching or hair loss may occur on rare occasions. Lethargy, ataxia, emesis, anorexia, diarrhoea, excessive salivation, hyperglycaemia, increased sensitivity to stimulation, bradycardia or bradypnea may be observed. Signs are transitory and generally resolve without treatment within 24 hours.
In very rare instances, certain sensitiv forms of dermatitis including pem this occur, contact your veterinari
The frequency of adverse re – very common (more
treatment)
-
– common (more than
-
– uncommon (more than
may develop skin irritation at the application site. Other -like conditions may occur in even rarer instances. Should mptly for treatment advice and discontinue use of the product.
s defined using the following convention:
in 10 animals displaying adverse reactions during the course of one
less than 10 animals in 100 animals)
1 but less than 10 animals in 1,000 animals)
rare very
t less than 10 animals in 10,000 animals)
1 animal in 10,000 animals, including isolated reports).
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.
RGET SPECIES
7.
8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
Dosage:
The recommended minimum dose is 6.7 mg/kg bodyweight (b.w.) for fipronil, 6 mg/kg for (S)-methoprene and 8 mg/kg for amitraz.
Spot-on use
Treatment schedule:
Monthly intervals throughout the tick and/or flea seasons, based on local epidemi
ical situations.
9.
ADVICE ON CORRECT ADMINISTRATION
1.
2.
Separate one blister from the others by tearing along perforation.
Use a pair of scissors to cut the blister along the dotted line (or fold on the corner as shown and pull the foil away).
3.
4.
Remove the pipette and hold it upright. Cut off the pipette ti Part the coat until the skin is visible. Place the tip of the pipe
5.
apply about half of the contents half way down the neck shoulder blades. Repeat the application at the base of the empty pipette.
Apply onto dry skin where the animal cannot lick it off a each other following treatment.
ith a pair of scissors.
on the skin. Squeeze pipette, en the base of the skull and the in front of the shoulder blades to
d make sure that animals do not lick
CERTIFECT treatment causes detachment of ticks when applied to a dog with a pre-existing infestation, disrupts attachment and rapidly kills ticks within 24 hours thus inhibiting the blood meal and the concomitant risk of transmission of tick-borne pathogens. The risk of developing canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis for 4 weeks is thereby indirectly reduced.
Remains effective after exposure to sunlight or if the animal becomes wet after rain, bathing, or water immersion. However, shampooing or immersion of the animal in water directly after treatment or frequent shampooing may reduce the duration of activity. Treated animals should not be bathed until 48 hours after treatment. If the dog requires shampooing, it is better to do so before applying the veterinary medicinal product.
All stages of fleas can infest soft furnishings. In case o areas should be treated wi
After treatment with after infestation wit cannot be excluded excluded if conditi
's basket, bedding and regular resting areas such as carpets and ive flea infestation and at the beginning of the control measures these itable environmental product and then vacuumed regularly.
T, ticks will generally be killed and fall off the dog within 24 hours
Not ap
10. WIT
aving a blood meal. However the attachment of single ticks after treatment is reason the transmission of infectious diseases cannot be completely unfavourable.
AL PERIOD
CIAL STORAGE PRECAUTIONS
out of the sight and reach of children. re in the original package.
Do not use after the expiry date stated on the outer package after EXP.
12. SPECIAL WARNINGS
Special precautions for use in animals:
Avoid contact with the dog's eyes.
For spot-on application only. Do not administer orally or via any other route.
The treated area may appear wet or oily after treatment.
In the absence of additional safety studies, do not repeat the treatment at intervals of less than 2weeks, do not treat puppies less than 8 weeks of age and dogs less than 2 kg bodyweight.
Dogs should be prevented from accessing streams and rivers for 48-hours following treatment.
Known side-effects of amitraz and its metabolites are due to alpha-2-adreno-receptor agonist effects. They may consist of hypersalivation, vomiting, lethargy, hyperglycaemia, bradycardia or bradypnea. Signs are transitory and generally resolve without treatment within 24 hours.
If symptoms are severe or persist alternatively use antidote (atipamezole hydrochloride).
The risk of experiencing adverse reactions may increase with overdosing, so animals should always be treated with the correct pipette size adapted to the body weight.
This veterinary medicinal product contains amitraz, which is a monoamine oxidase inhibitor (MAOI); therefore, in the absence of studies, this veterinary medicinal product should not be used on dogs treated with MAOI.
Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product may cause skin sensitisation, allergic reactions and mild eye irritation in humans. Animals or persons with a known hypersensitivity to any of the active ingredients or excipients should avoid contact which, on very rare occasions, can cause respiratory irritation and dermal reactions in certain individuals. The use of protective gloves is recommended. Avoid direct contact with the application site. Children should not be allowed to play with treated dogs until the application site is dry. It is therefore recommended that dogs are not treated during the day, but during the early evening, and that recently treated animals are not allowed to sleep with
owners, especially children.
This veterinary medicinal product humans.
Amitraz is a monoamine oxidase i medication should take particular
ins amitraz, which can lead to neurological side-effects in
To minimise the potential fo Do not smoke, drink or ea Wash hands thoroughly Used pipettes should be
nhibitor (MAOI); therefore, people taking MAOI-containing care and avoid direct contact with the product.
lation, apply in the open air or in a well ventilated area.
handling.
d of immediately. Stored pipettes must be kept in the intact foil
package.
In case of accident gets into the eye In case of incorrect the physician.
If side effects the physician.
ge onto skin, wash off immediately with soap and water. If its accidentally ould be thoroughly flushed with water.
, seek medical advice immediately and show the package leaflet or the label to
oted, seek immediate medical assistance and show the package leaflet or label to
Pregnancy and lactation:
Ca ed during pregnancy and lactation.
Overdose:
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses up to 3 times the maximum recommended dose.Safety has been also demonstrated with up to 5 times the recommended dose in healthy adult dogs (treated up to 6 times at two-week intervals) and in puppies (aged 8 weeks treated once).
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY
Medicines should not be disposed of via wastewater or household waste.
Any unused veterinary medicinal product or waste materials derived from it should be disposed of in accordance with local requirements and should not enter water courses as this may be dangerous for fish and aquatic organisms.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
Detailed information on this product is available on the website of the European Medicines Agency.
15. OTHER INFORMATION
Each strength of the veterinary medicinal product is available in cards with 1 pipette and in carton boxes of 3 pipettes.
Not all pack sizes may be marketed.
For animal treatment only.
To be supplied only on veterinary prescription.
PACKAGE LEAFLET FOR (Card of 1 pipette)
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg< CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder
MERIAL Ch
29, avenue Tony Garnier
FR-69007 Lyon
France.
Manufacturer responsible for the batch release:
MERIAL
4, Chemin du Calquet
FR-31000 Toulouse Cedex
France rv
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS
Spot-on solution.
Clear amber to yellowish solution.
Each unit dose (dual cavity pipette) delivers:
| CERTIFECT spot-on solution _____ /XT | Volume of unit dose (ml) | Fipronil (mg) | (S)-methoprene (mg) | Amitraz (mg) |
| dogs 2–10 kg | 1.07 | 67.0 | 60.3 | 80.0 |
| dogs 10–20 kg | 2.14 | 134.0 | 120.6 | 160.0 |
| dogs 20–40 kg | 4.28 | 268.0 | 241.2 | 320.0 |
| ^/dogs 40–60 kg ----Tk ------------ | 6.42 | 402.0 | 361.8 | 480.0 |
Excipients essential for proper administration: butylhydroxyanisole (0.02 %) and butylhydroxytoluene (0.01 %).
4. INDICATIONS
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulat Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and flea (Ctenocephalides felis and Ctenocephalides canis).
Treatment of infestations by chewing lice (Trichodectes canis ).
Prevention of environmental flea contamination by inhibiting the development of a stages.
mature
Dermatitis
The product can be used as part of a treatment strategy for the control of Flea (FAD).
Elimination of fleas and ticks within 24 hours. One treatment prevents furt by ticks and for up to 5 weeks by fleas.
The treatment indirectly reduces the risk of transmission of tick-bo monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis)
estations for 5 weeks
5. CONTRAINDICATIONS
ses (canine babesiosis, fected ticks for 4 weeks.
Do not use on sick (e.g. systemic diseases, diabetes, feve Do not use in rabbits and cats.
6. ADVERSE REACTIONS
nvalescent animals.
Transient skin reactions at the application site
scolouration, local hair loss, itching, redness)
and general itching or hair loss may occur on rare occasions. Lethargy, ataxia, emesis, anorexia, diarrhoea, excessive salivation, hyperglycaemia, increased sensitivity to stimulation, bradycardia or bradypnea may be observed. Signs are transitory and generally resolve without treatment within 24 hours.
In very rare instances, certain sensitive dogs may develop skin irritation at the application site. Other forms of dermatitis including pemphigus-like conditions may occur in even rarer instances. Should this occur, contact your veterinarian promptly for treatment advice and discontinue use of the product.
The frequency of adverse
s is defined using the following convention:
very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) common (more
uncommon (more than 1 but less than 10 animals in 1,000 animals)
rare (more than 1 but less than 10 animals in 10,000 animals)
very rare (less than 1 animal in 10,000 animals, including isolated reports).
If you noti veterinary
GET SPECIES
serious effects or other effects not mentioned in this leaflet, please inform your
8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
ter on the corner as
a pair of scissors.
skin. Squeeze pipette, e base of the skull and the ront of the shoulder blades to
tuations.
Dosage:
The recommended minimum dose is 6.7 mg/kg bodyweight (b.w.) for fipronil, 6 mg/kg for (S)-methoprene and 8 mg/kg for amitraz.
Spot-on use
Treatment schedule:
Monthly intervals throughout the tick and/or flea seasons, based on local epidemiologi
9.
1.
2.
3.
4.
ADVICE ON CORRECT ADMINISTRATION
Use a pair of scissors to cut the blister along the dotted line shown, and pull the foil away).
Remove the pipette and hold it upright. Cut off the pipette tip w Part the coat until the skin is visible. Place the tip of the pipe apply about half of the contents half way down the neck bet shoulder blades. Repeat the application at the base of the empty pipette.
Apply onto dry skin where the animal cannot lick it off a each other following treatment.
sure that animals do not lick
CERTIFECT treatment causes detachment of ticks when applied to a dog with a pre-existing infestation, disrupts attachment and rapidly kills ticks within 24 hours thus inhibiting the blood meal and the concomitant risk of transmission of tick-borne pathogens. The risk of developing canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis for 4 weeks is thereby indirectly reduced.
Remains effective after exposure to sunlight or if the animal becomes wet after rain, bathing, or water immersion. However, shampooing or immersion of the animal in water directly after treatment or frequent shampooing may reduce the duration of activity. Treated animals should not be bathed until 48 hours after treatment. If the dog requires shampooing, it is better to do so before applying the veterinary medicinal product.
After treatment with CER
All stages of fleas can infest the soft furnishings. In case of massive areas should be treated with a su
asket, bedding and regular resting areas such as carpets and ea infestation and at the beginning of the control measures these e environmental product and then vacuumed regularly.
, ticks will generally be killed and fall off the dog within 24 hours ving a blood meal. However the attachment of single ticks after treatment on the transmission of infectious diseases cannot be completely excluded if conditions are unfavourable.
after infestation without cannot be excluded. For this
Not applic
11.
10. WITHD
L PERIOD
AL STORAGE PRECAUTIONS
of the sight and reach of children.
in the original package.
ot use after the expiry date stated on the outer package after EXP.
12. SPECIAL WARNINGS
ent.
agonist effects. ia or bradypnea.
Special precautions for use in animals:
Avoid contact with the dog's eyes.
For spot-on application only. Do not administer orally or via any other route.
The treated area may appear wet or oily after treatment.
In the absence of additional safety studies, do not repeat the treatment at intervals of le 2 weeks, do not treat puppies less than 8 weeks of age, and dogs less than 2 kg bodyw
Dogs should be prevented from accessing streams and rivers for 48-hours followi
Known side-effects of amitraz and its metabolites are due to alpha-2-adreno-rece They may consist of hypersalivation, vomiting, lethargy, hyperglycaemia, bradyc Signs are transitory and generally resolve without treatment within 24 hours.
If symptoms are severe or persist alternatively use antidote (atipamezole hydroch
loride).
The risk of experiencing adverse reactions may increase with overdosing, so animals should always be treated with the correct pipette size adapted to the body weight.
ne oxidase inhibitor (MAOI); ould not be used on dogs
This veterinary medicinal product contains amitraz, which is a therefore, in the absence of studies, this veterinary medicinal pr treated with MAOI.
veterinary medicinal product to
Special precautions to be taken by the person administeri animals:
This veterinary medicinal product may cause skin sensitisation, allergic reactions and mild eye irritation in humans. Animals or persons with a known hypersensitivity to any of the active ingredients or excipients should avoid contact which, on very rare occasions, can cause respiratory irritation and dermal reactions in certain individuals. The use of protective gloves is recommended. Avoid direct contact with the application site. Children should not be allowed to play with treated dogs until the application site is dry. It is therefore recommended that dogs are not treated during the day, but during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children.
This veterinary medicinal product contains amitraz, which can lead to neurological side-effects in humans. Amitraz is a monoamine inhibitor (MAOI); therefore, people taking MAOI-containing medication should take part lar care and avoid direct contact with the product.. To minimise the potential for in ion, apply in the open air or in a well ventilated area. Do not smoke, drink or eat whilst handling.
Wash hands thoroughly after use.
Used pipettes should be disposed of immediately. Stored pipettes must be kept in the intact foil
package.
In case of accidental s gets into the eyes, the In case of incorrect us the physician.
If side effects the physician.
illage onto skin, wash off immediately with soap and water. If it accidentally should be thoroughly flushed with water.
, seek medical advice immediately and show the package leaflet or the label to
Pregnane
Can be
, seek immediate medical assistance and show the package leaflet or label to
ctation:
ring pregnancy and lactation.
Overdose:
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses up to 3 times the maximum recommended dose.
Safety has been also demonstrated with up to 5 times the recommended dose in healthy adult dogs (treated up to 6 times at two-week intervals) and in puppies (aged 8 weeks treated once).
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR
Medicines should not be disposed of via wastewater or household waste.
Any unused veterinary medicinal product or waste materials derived from it should be disposed of in accordance with local requirements and should not enter water courses as this may be dangerous for fish and aquatic organisms.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
.................................
Detailed information on this product is available on the website of the European Medicines Agency
. rv
15. OTHER INFORMATION
Each strength of the veterinary medicinal product is available in cards with 1 pipette and in carton boxes of 3 pipettes.
Not all pack sizes may be marketed.
For animal treatment only.
To be supplied only on veterinary prescription.
PACKAGE LEAFLET FOR (Card of 1 pipette)
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg< CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT
Marketing authorisation holder
MERIAL Ch
29, avenue Tony Garnier
FR-69007 Lyon
France.
Manufacturer responsible for the batch release:
MERIAL
4, Chemin du Calquet
FR-31000 Toulouse Cedex
France rv
-
2. NAME OF THE VETERINARY MEDICINAL PRODUCT
CERTIFECT 67 mg/ 60.3 mg/ 80 mg spot-on solution for dogs 2–10 kg
CERTIFECT 134 mg/ 120.6 mg/ 160 mg spot-on solution for dogs 10–20 kg
CERTIFECT 268 mg/ 241.2 mg/ 320 mg spot-on solution for dogs 20–40 kg
CERTIFECT 402 mg/ 361.8 mg/ 480 mg spot-on solution for dogs 40–60 kg
-
3. STATEMENT OF THE ACTIVE SUBSTANCES AND OTHER INGREDIENTS
Spot-on solution.
Clear amber to yellowish solution.
Each unit dose (dual cavity pipette) delivers:
| CERTIFECT spot-on solution _____ /XT | Volume of unit dose (ml) | Fipronil (mg) | (S)-methoprene (mg) | Amitraz (mg) |
| dogs 2–10 kg | 1.07 | 67.0 | 60.3 | 80.0 |
| dogs 10–20 kg | 2.14 | 134.0 | 120.6 | 160.0 |
| dogs 20–40 kg | 4.28 | 268.0 | 241.2 | 320.0 |
| ^/dogs 40–60 kg ----Tk ------------ | 6.42 | 402.0 | 361.8 | 480.0 |
Excipients essential for proper administration: butylhydroxyanisole (0.02 %) and butylhydroxytoluene (0.01 %).
4. INDICATIONS
Treatment and prevention of infestations in dogs by ticks (Ixodes ricinus, Dermacentor reticulat Rhipicephalus sanguineus, Ixodes scapularis, Dermacentor variabilis, Haemaphysalis elliptica, Haemaphysalis longicornis, Amblyomma americanum and Amblyomma maculatum) and flea (Ctenocephalides felis and Ctenocephalides canis).
Treatment of infestations by chewing lice (Trichodectes canis ).
Prevention of environmental flea contamination by inhibiting the development of a stages.
mature
Dermatitis
The product can be used as part of a treatment strategy for the control of Flea (FAD).
Elimination of fleas and ticks within 24 hours. One treatment prevents furt by ticks and for up to 5 weeks by fleas.
The treatment indirectly reduces the risk of transmission of tick-bo monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis)
estations for 5 weeks
5. CONTRAINDICATIONS
ses (canine babesiosis, fected ticks for 4 weeks.
Do not use on sick (e.g. systemic diseases, diabetes, feve Do not use in rabbits and cats.
6. ADVERSE REACTIONS
nvalescent animals.
Transient skin reactions at the application site
scolouration, local hair loss, itching, redness)
and general itching or hair loss may occur on rare occasions. Lethargy, ataxia, emesis, anorexia, diarrhoea, excessive salivation, hyperglycaemia, increased sensitivity to stimulation, bradycardia or bradypnea may be observed. Signs are transitory and generally resolve without treatment within 24 hours.
In very rare instances, certain sensitive dogs may develop skin irritation at the application site. Other forms of dermatitis including pemphigus-like conditions may occur in even rarer instances. Should this occur, contact your veterinarian promptly for treatment advice and discontinue use of the product.
The frequency of adverse
s is defined using the following convention:
very common (more than 1 in 10 animals displaying adverse reactions during the course of one treatment) common (more
uncommon (more than 1 but less than 10 animals in 1,000 animals)
rare (more than 1 but less than 10 animals in 10,000 animals)
very rare (less than 1 animal in 10,000 animals, including isolated reports).
If you noti veterinary
GET SPECIES
serious effects or other effects not mentioned in this leaflet, please inform your
8. DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
ter on the corner as
a pair of scissors.
skin. Squeeze pipette, e base of the skull and the ront of the shoulder blades to
tuations.
Dosage:
The recommended minimum dose is 6.7 mg/kg bodyweight (b.w.) for fipronil, 6 mg/kg for (S)-methoprene and 8 mg/kg for amitraz.
Spot-on use
Treatment schedule:
Monthly intervals throughout the tick and/or flea seasons, based on local epidemiologi
9.
1.
2.
3.
4.
ADVICE ON CORRECT ADMINISTRATION
Use a pair of scissors to cut the blister along the dotted line shown, and pull the foil away).
Remove the pipette and hold it upright. Cut off the pipette tip w Part the coat until the skin is visible. Place the tip of the pipe apply about half of the contents half way down the neck bet shoulder blades. Repeat the application at the base of the empty pipette.
Apply onto dry skin where the animal cannot lick it off a each other following treatment.
sure that animals do not lick
CERTIFECT treatment causes detachment of ticks when applied to a dog with a pre-existing infestation, disrupts attachment and rapidly kills ticks within 24 hours thus inhibiting the blood meal and the concomitant risk of transmission of tick-borne pathogens. The risk of developing canine babesiosis, monocytic ehrlichiosis, granulocytic anaplasmosis and borreliosis for 4 weeks is thereby indirectly reduced.
Remains effective after exposure to sunlight or if the animal becomes wet after rain, bathing, or water immersion. However, shampooing or immersion of the animal in water directly after treatment or frequent shampooing may reduce the duration of activity. Treated animals should not be bathed until 48 hours after treatment. If the dog requires shampooing, it is better to do so before applying the veterinary medicinal product.
After treatment with CER
All stages of fleas can infest the soft furnishings. In case of massive areas should be treated with a su
asket, bedding and regular resting areas such as carpets and ea infestation and at the beginning of the control measures these e environmental product and then vacuumed regularly.
, ticks will generally be killed and fall off the dog within 24 hours ving a blood meal. However the attachment of single ticks after treatment on the transmission of infectious diseases cannot be completely excluded if conditions are unfavourable.
after infestation without cannot be excluded. For this
Not applic
11.
10. WITHD
L PERIOD
AL STORAGE PRECAUTIONS
of the sight and reach of children.
in the original package.
ot use after the expiry date stated on the outer package after EXP.
-
12. SPECIAL WARNINGS
ent.
agonist effects. ia or bradypnea.
Special precautions for use in animals:
Avoid contact with the dog's eyes.
For spot-on application only. Do not administer orally or via any other route.
The treated area may appear wet or oily after treatment.
In the absence of additional safety studies, do not repeat the treatment at intervals of le 2 weeks, do not treat puppies less than 8 weeks of age, and dogs less than 2 kg bodyw
Dogs should be prevented from accessing streams and rivers for 48-hours followi
Known side-effects of amitraz and its metabolites are due to alpha-2-adreno-rece They may consist of hypersalivation, vomiting, lethargy, hyperglycaemia, bradyc Signs are transitory and generally resolve without treatment within 24 hours.
If symptoms are severe or persist alternatively use antidote (atipamezole hydroch
loride).
The risk of experiencing adverse reactions may increase with overdosing, so animals should always be treated with the correct pipette size adapted to the body weight.
ne oxidase inhibitor (MAOI); ould not be used on dogs
This veterinary medicinal product contains amitraz, which is a therefore, in the absence of studies, this veterinary medicinal pr treated with MAOI.
veterinary medicinal product to
Special precautions to be taken by the person administeri animals:
This veterinary medicinal product may cause skin sensitisation, allergic reactions and mild eye irritation in humans. Animals or persons with a known hypersensitivity to any of the active ingredients or excipients should avoid contact which, on very rare occasions, can cause respiratory irritation and dermal reactions in certain individuals. The use of protective gloves is recommended. Avoid direct contact with the application site. Children should not be allowed to play with treated dogs until the application site is dry. It is therefore recommended that dogs are not treated during the day, but during the early evening, and that recently treated animals are not allowed to sleep with owners, especially children.
This veterinary medicinal product contains amitraz, which can lead to neurological side-effects in humans. Amitraz is a monoamine inhibitor (MAOI); therefore, people taking MAOI-containing medication should take part lar care and avoid direct contact with the product.. To minimise the potential for in ion, apply in the open air or in a well ventilated area. Do not smoke, drink or eat whilst handling.
Wash hands thoroughly after use.
Used pipettes should be disposed of immediately. Stored pipettes must be kept in the intact foil
package.
In case of accidental s gets into the eyes, the In case of incorrect us the physician.
If side effects the physician.
illage onto skin, wash off immediately with soap and water. If it accidentally should be thoroughly flushed with water.
, seek medical advice immediately and show the package leaflet or the label to
Pregnane
Can be
, seek immediate medical assistance and show the package leaflet or label to
ctation:
ring pregnancy and lactation.
Overdose:
Safety was demonstrated in breeding, pregnant and lactating animals treated at 28-day intervals with multiple consecutive doses up to 3 times the maximum recommended dose.
Safety has been also demonstrated with up to 5 times the recommended dose in healthy adult dogs (treated up to 6 times at two-week intervals) and in puppies (aged 8 weeks treated once).
-
13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR
Medicines should not be disposed of via wastewater or household waste.
Any unused veterinary medicinal product or waste materials derived from it should be disposed of in accordance with local requirements and should not enter water courses as this may be dangerous for fish and aquatic organisms.
Ask your veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment.
-
14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED
.................................
Detailed information on this product is available on the website of the European Medicines Agency
. rv
-
15. OTHER INFORMATION